Healthy Volunteers
Conditions
Keywords
E6007, Healthy Japanese male subjects
Brief summary
This is a single-center, placebo-controlled, randomized, ascending dose, double-blind study. This study will be evaluating ascending doses of 50, 100, 200, and 400 mg of E6007. This study consists of 5 steps, 1 to 5. In steps 1 to 4 (at ascending doses of 50, 100, 200, and 400 mg), subjects will be randomly assigned in a 6:2 ratio (E6007: placebo) to receive single dose of the study drug under fasted condition. Following 3 days of washout period, subject will receive the study drug once daily for 7 days starting on the fifth day from the single dose administration. For step 3 (200 mg), subjects will subsequently have at least 17 days of washout period before being escalated to step 5 (200 mg) to receive single dose of E6007 under fed condition, to evaluate food effect of the study drug.
Interventions
DRUGE6007
DRUGE6007 matching placebo
Sponsors
Eisai Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
20 Years to 44 Years
Healthy volunteers
Yes
Inclusion criteria
Subjects must meet all of the following criteria to be included in this study: 1. Healthy Japanese male subjects aged 20 to 44 years at the time of informed consent. 2. Has voluntarily consented, in writing, to participate in this study. 3. Has been thoroughly briefed on the conditions for participation in the study, and is willing and able to comply with the conditions.
Exclusion criteria
Subjects who meet any of the following criteria will be excluded from this study: 1. Has a clinically significant medical condition requiring treatment within 8 weeks before the initial study drug administration, or a history of clinically significant infection requiring treatment within 4 weeks before the initial drug administration. 2. History of surgical treatment such as resection of the liver, kidney, or Gastrointestinal tract, that may affect the Pharmacokinetic profiles of study drugs. 3. Ineligible for study participation in the opinion of the investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma E6007 concentration over time period - AUC (0-tau) (AUC from time zero to time tau over a dosing interval at steady state) | Up to 15 days |
| Plasma E6007 concentration over time period - CL/F (Apparent clearance) | Up to 15 days |
| Plasma E6007 concentration over time period - Vz/F (Apparent volume of distribution) | Up to 15 days |
| Plasma E6007 concentration over time period - Css,max (maximum steady state concentration) | Up to 15 days |
| Safety and tolerability of E6007 as a measure of Adverse events | Screening and up to 17 days after last administration of drug |
| Plasma E6007 concentration over time period - Cmax (maximum concentration) | Up to 15 days |
| Plasma E6007 concentration over time period - tmax (Time to achieve maximum concentration (Cmax)) | Up to 15 days |
| Plasma E6007 concentration over time period - AUC (0-t) (Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration) | Up to 15 days |
| Plasma E6007 concentration over time period - AUC (0-inf) (AUC extrapolated to infinity) | Up to 15 days |
| Plasma E6007 concentration over time period - t1/2 (Terminal phase half-life) | Up to 15 days |
Secondary
| Measure | Time frame |
|---|---|
| Geometric mean proportion (fed:fasted) of Cmax, AUC(0-t) and AUC(0-inf) for 200mg E6007 dose | Up to 5 days |
| Evaluate relationship between E6007 plasma concentrations and electrocardiogram (ECG) parameter (QTcF) | Up to 15 days |
| Dose proportionality under fasted conditions with Cmax, AUC (0-t), AUC(0-inf), Cssmax and AUC(0-t) | Up to 15 days |
Countries
Japan
Outcome results
None listed